The stock of BioNexus Gene Lab Corp (NASDAQ: BGLC) has increased by 295.28 when compared to last closing price of 3.07.Despite this, the company has seen a gain of 354.49% in its stock price over the last five trading days. globenewswire.com reported 2025-04-30 that KUALA LUMPUR, Malaysia, April 30, 2025 (GLOBE NEWSWIRE) — BioNexus Gene Lab Corp. (Nasdaq: BGLC), a biotechnology company specializing in precision diagnostics and specialty chemical solutions, today announced that it has received official notification from The Nasdaq Stock Market LLC (“Nasdaq”) confirming the Company has regained full compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share.
Is It Worth Investing in BioNexus Gene Lab Corp (NASDAQ: BGLC) Right Now?
The 36-month beta value for BGLC is at 1.80.
The public float for BGLC is 1.17M, and currently, shorts hold a 1.36% of that float. The average trading volume for BGLC on July 01, 2025 was 622.40K shares.
BGLC’s Market Performance
BGLC’s stock has seen a 354.49% increase for the week, with a 182.87% rise in the past month and a 413.32% gain in the past quarter. The volatility ratio for the week is 10.08%, and the volatility levels for the past 30 days are at 10.88% for BioNexus Gene Lab Corp The simple moving average for the past 20 days is 255.46% for BGLC’s stock, with a 263.36% simple moving average for the past 200 days.
BGLC Trading at 284.98% from the 50-Day Moving Average
After a stumble in the market that brought BGLC to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 44.46% of gains for the given period.
Stock Fundamentals for BGLC
Current profitability levels for the company are sitting at:
- -0.23 for the present operating margin
- 0.14 for the gross margin
The net margin for BioNexus Gene Lab Corp stands at -0.23. The total capital return value is set at -0.27. Equity return is now at value -24.75, with -20.52 for asset returns.
Based on BioNexus Gene Lab Corp (BGLC), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -15.11. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -128.18.
Currently, EBITDA for the company is -1.42 million with net debt to EBITDA at 0.45. When we switch over and look at the enterprise to sales, we see a ratio of 2.08. The receivables turnover for the company is 5.52for trailing twelve months and the total asset turnover is 0.98. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.19.
Conclusion
In conclusion, BioNexus Gene Lab Corp (BGLC) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
